Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Specifically, Karo's chemists are using Elsevier's Reaxys and Reaxys Medicinal Chemistry solutions. These tools give researchers access to biological and chemistry data from periodicals, peer-reviewed journal articles, and patents.

The financial details of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.